EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Apogee Therapeutics's Enterprise Value is $2,189.98 Mil.
Apogee Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 was $-96.19 Mil. Therefore, Apogee Therapeutics's EV-to-FCF for today is -22.77.
The historical rank and industry rank for Apogee Therapeutics's EV-to-FCF or its related term are showing as below:
APGE'
s EV-to-FCF Range Over the Past 10 Years
Min: -104.21 Med: 0 Max: 0
Current: -22.77
APGE's EV-to-FCF is ranked worse than 100% of 381
companies
in the Biotechnology industry
Industry Median: 7.56
vs APGE: -22.77
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The historical data trend for Apogee Therapeutics's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Apogee Therapeutics's EV-to-FCF
For the Biotechnology subindustry, Apogee Therapeutics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Apogee Therapeutics's EV-to-FCF Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Apogee Therapeutics's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Apogee Therapeutics's EV-to-FCF falls into.
Apogee Therapeutics's current Enterprise Value is $2,189.98 Mil.
Apogee Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-96.19 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Apogee Therapeutics's PE Ratio for today is calculated as:
Apogee Therapeutics's share price for today is $53.75.
Apogee Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.201.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Apogee Therapeutics EV-to-FCF Related Terms
Thank you for viewing the detailed overview of Apogee Therapeutics's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Apogee Therapeutics (Apogee Therapeutics) Business Description
Apogee Therapeutics Inc is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD) and related inflammatory and immunology (I&I) indications with high unmet need. Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating advanced antibody engineering to optimize half-life and other properties. Its two most advanced programs are APG777 and APG808, which they initially develop for treating AD and COPD, respectively. With its broad pipeline and depth of expertise, the company believes it can deliver value and meaningful benefits to patients underserved by today's standard of care.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
APGE has been successfully added to your